Alteogen Achieves Record High with 215.9 Billion Won Sales and 106.9 Billion Won Operating Profit in 2025

Shareholder Return Policy Initiated,
Including 20 Billion Won Cash Dividend

Alteogen achieved its highest-ever performance last year, recording consolidated sales of 215.9 billion won and operating profit of 106.9 billion won. Net profit for the year was tallied at 144.3 billion won.

On February 27, Alteogen announced through a regulatory filing that sales increased by 110% year-on-year, while operating profit surged by 321%. Net profit also expanded by 138%. The company explained that growth was driven by increased revenue recognition from the commercialization of its platform technology.

The company possesses proprietary technology, Hybrozyme, which converts intravenous (IV) formulations to subcutaneous (SC) formulations. This technology has been licensed out to seven global pharmaceutical companies, including MSD, AstraZeneca, Sandoz, Daiichi Sankyo, GSK, and Intas. Revenue from these deals has been fully reflected since entering the commercialization stage in the second half of last year.

Notably, milestone revenue was generated following the approval of the subcutaneous formulation of the immuno-oncology drug Keytruda in the US and Europe. Upfront payments from the AstraZeneca contract for the SC conversion of its oncology drug also contributed to improved results. Increases in sales from the supply of ALT-B4 and royalty revenue from expanded sales of the Herceptin biosimilar ‘Annogta’ in China were also reflected.

Alteogen has also initiated its shareholder return policy. The board of directors resolved to pay a cash dividend totaling 20 billion won. The company plans to continue expanding its shareholder return policy, including dividends, based on a stable earnings foundation going forward.

Alteogen CEO Jeon Taeyeon stated, “We are currently conducting clinical trials for the SC conversion of Daiichi Sankyo’s Enhertu and AstraZeneca’s oncology drugs using our technology. As these blockbuster products, which have already proven their marketability, are converted to SC formulations, their competitiveness will be further enhanced. Since most patients prefer SC products, we anticipate that more global pharmaceutical companies will choose to work with Alteogen in the future.”

This content was produced with the assistance of AI translation services.